Patents Assigned to JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD
-
Patent number: 11771773Abstract: Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.Type: GrantFiled: October 16, 2017Date of Patent: October 3, 2023Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Li Dong, Ge Wang, Di Hu, Yundong Sun, Hengli Yuan
-
Patent number: 11667631Abstract: The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.Type: GrantFiled: May 16, 2017Date of Patent: June 6, 2023Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Peng Gao, Wenhua Xiu, Shaobao Wang, Lei Liu, Rudi Bao
-
Patent number: 11661437Abstract: Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.Type: GrantFiled: January 31, 2019Date of Patent: May 30, 2023Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Yidong Su, Xiaopo Chen, Jun Wang, Rudi Bao
-
Patent number: 11608332Abstract: Provided are an FGFR4 inhibitor with the structure of formula (I) and a preparation method and use thereof. The series of compounds of formula (I) have a very strong inhibitory effect on the FGFR4 kinase activity, and have a very high selectivity; and the same can be widely used to prepare drugs for treating cancers, in particular, liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and it is expected that the same can be developed into a new generation of FGFR4 inhibitor drugs.Type: GrantFiled: August 11, 2017Date of Patent: March 21, 2023Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Peng Gao, Guangjun Sun, Songliang Tan, Lei Liu, Rudi Bao
-
Patent number: 11472882Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.Type: GrantFiled: February 1, 2019Date of Patent: October 18, 2022Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Rudi Bao, Haiqing Hua, Suxia Liu, Fujun Zhang, Ting Wang
-
Patent number: 11155534Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.Type: GrantFiled: August 6, 2020Date of Patent: October 26, 2021Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Zhongke Chen, Fuping Liu, Lei Liu, Rudi Bao
-
Patent number: 11136324Abstract: An amide derivative inhibitor and a preparation method and an application thereof. Specifically relating to the compound shown in general formula (I), a preparation method for same, a pharmaceutical composition comprising said compound, and an application of same as an ASK inhibitor for the treatment of neurodegenerative disease, cardiovascular disease, inflammation, autoimmune and metabolic disease, each of the substituents in the general formula (I) being as defined in the description.Type: GrantFiled: March 2, 2018Date of Patent: October 5, 2021Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Peng Gao, Guangjun Sun, Shaobao Wang, Fujun Zhang, Lei Liu, Rudi Bao
-
Publication number: 20210032249Abstract: An amide derivative inhibitor and a preparation method and an application thereof are provided. Specifically, a compound shown in general formula (I), a preparation method for same, a pharmaceutical composition containing the compound, and an application of same as an ASK inhibitor are provided. The disclosed compounds can be used for the treatment of neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune and metabolic diseases. Each of the substituents in the general formula (I) is as defined in the description.Type: ApplicationFiled: March 2, 2018Publication date: February 4, 2021Applicants: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Peng GAO, Guangjun SUN, Shaobao WANG, Fujun ZHANG, Lei LIU, Rudi BAO
-
Patent number: 10836786Abstract: Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyOphenyl)-2-ethoxy-6-(methylhydroxyl) tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, which has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.Type: GrantFiled: July 21, 2017Date of Patent: November 17, 2020Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Xiang Li, Jun Yu, Haizhou Yu, Jinjia Wang, Lei He, Zuyin Du
-
Patent number: 10759782Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.Type: GrantFiled: December 23, 2016Date of Patent: September 1, 2020Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanhgai Hansoh Biomecial Co., Ltd.Inventors: Zhongke Chen, Fuping Liu, Lei Liu, Rudi Bao
-
Patent number: 10538506Abstract: The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development.Type: GrantFiled: November 9, 2015Date of Patent: January 21, 2020Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Hongwei Tang, Changan Sun, Ruijun Wang, Hengli Yuan
-
Patent number: 10464915Abstract: Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(?-D-glucopyranose-1-yl)-4?-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.Type: GrantFiled: May 22, 2017Date of Patent: November 5, 2019Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Xiang Li, Lei He, Jun Yu, Jinjia Wang, Zuyin Du
-
Patent number: 10428081Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.Type: GrantFiled: December 3, 2018Date of Patent: October 1, 2019Assignees: SHANGHAI HANSOH BIOMEDICAL CO., LTD., JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.Inventors: Mingsong Wei, Guangjun Sun, Songliang Tan, Peng Gao, Shaobao Wang, Wenhua Xiu, Fujun Zhang, Rudi Bao
-
Patent number: 10259820Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.Type: GrantFiled: September 30, 2015Date of Patent: April 16, 2019Assignees: SHANGHAI HANSOH BIOMEDICAL CO., LTD., JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.Inventors: Mingsong Wei, Guangjun Sun, Songliang Tan, Peng Gao, Shaobao Wang, Wenhua Xiu, Fujun Zhang, Rudi Bao
-
Publication number: 20190077791Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.Type: ApplicationFiled: December 23, 2016Publication date: March 14, 2019Applicants: Jiangsu Hansoh Pharmaceutical Group co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.Inventors: Zhongke CHEN, Fuping LIU, Lei LIU, Rudi BAO
-
Patent number: 10208065Abstract: Crystalline free bases and crystalline acid salts of 9-((8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-yl)thio)-4-methyl-2H-[1,4]oxaazido[3,2-c]quinoline-3(4H)-one are disclosed as C-Met inhibitors. Their preparation methods and uses are also described. In particular, crystal forms I, II, III and IV of the free base; crystal form I of the hydrochloride salt; crystal forms I and II of the sulfate salt; crystal forms I, II, III and IV of the phosphate salt; crystal forms I, II, III, IV and V of the mesylate salt; crystal forms I, II and III of the p-toluenesulfonate salt; and crystal forms I, II and III of the 1,5-naphthalenedisulfonate salt are disclosed. Also disclosed are methods for preparing the above-mentioned crystal forms, pharmaceutical compositions thereof, methods for regulating the catalytic activity of a protein kinase, and methods of treating protein kinase-related diseases.Type: GrantFiled: July 30, 2015Date of Patent: February 19, 2019Assignee: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.Inventors: Xiang Li, Aifeng Lv
-
Publication number: 20180282300Abstract: The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG. 1. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development.Type: ApplicationFiled: November 9, 2015Publication date: October 4, 2018Applicants: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Hongwei TANG, Changan SUN, Ruijun WANG, Hengli YUAN
-
Patent number: 9840525Abstract: A crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) is provided. Also provided is a preparation method and method of using the crystal form. Specifically, a crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) having an X-ray powder diffraction (XRPD) spectrum including diffraction peaks at 2?±0.20° of 5.08, 12.44, 13.18, 22.37, 23.37 and 28.56 is provided. The crystal form provided herein has high bioavailability, significant efficacy, good stability, high yield and high purity, and contributes to the selection and design of a drug administration route and the determination of process parameters of a pharmaceutical preparation, thereby improving drug production quality.Type: GrantFiled: July 21, 2015Date of Patent: December 12, 2017Assignee: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.Inventors: Ming Chen, Chengyao Tian, Mingli Zhao, Jun Yu, Baohai Yang, Aifeng Lu
-
Publication number: 20170313714Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.Type: ApplicationFiled: September 30, 2015Publication date: November 2, 2017Applicants: Shanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Mingsong WEI, Guangjun SUN, Songliang TAN, Peng GAO, Shaobao WANG, Wenhua XIU, Fujun ZHANG, Rudi BAO
-
Patent number: 9550747Abstract: The present invention relates to a new crystalline form of dapagliflozin represented by formula (I). The crystalline form has a characteristic absorption peak at about 4.318 (20.45) in an X-ray powder diffraction pattern shown by angle 2 theta and interplanar spacing (value d). It can be prepared by dissolving dapagliflozin in good organic solvents, adding poor solvents, stirring to crystallization, filtering and drying. The new crystalline form of dapagliflozin of the present invention has the following superior features: good solubility, low hygroscopicity, high stability and good preparation reproducibility.Type: GrantFiled: January 19, 2015Date of Patent: January 24, 2017Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.Inventors: Xifeng Zhu, Xiaobi Li, Tiancheng Zhang, Fuping Yuan